Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial [0.03%]
伊布替尼、来那度胺和利妥昔单抗治疗复发性套细胞淋巴瘤：北欧淋巴瘤组MCL6 Philemon试验的长期随访
Elin Forsgren,Rasmus R K Jørgensen,Hans Bentzen et al.
Elin Forsgren et al.
Relapsed or refractory mantle cell lymphoma (R/R MCL) remains difficult to treat, with outcomes dependent on the treatment regimen and remission duration after first-line therapy. Several non-chemotherapeutic regimens are under evaluation i...
Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine-induced adverse effects in an acute lymphoblastic leukemia patient-derived xenograft model [0.03%]
使用MCC950抑制NLRP3炎性体可降低ALL患者来源的异种移植模型中长春新碱引起的不良反应
Hana Starobova,Hannah McCalmont,Svetlana Shatunova et al.
Hana Starobova et al.
Vincristine is one of the most important chemotherapeutic drugs used to treat acute lymphoblastic leukemia (ALL). Unfortunately, vincristine often causes severe adverse effects, including sensory-motor neuropathies, weight loss, and overall...
Who owns that blood? Recontacting donors with results from genetic testing after allogeneic hematopoietic cell transplantation [0.03%]
谁拥有那些血液？异基因造血细胞移植后遗传检测结果的再联系捐赠者问题
Mirjam E Belderbos,Marc Bierings,Noa van Bergeijk et al.
Mirjam E Belderbos et al.
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry [0.03%]
抗凝和减细胞治疗对骨髓增殖性肿瘤患者房颤相关并发症的缓解：来自GSG-MPN生物注册登记的数据启示
Hyunyee Rosa Cho,Susanne Isfort,Kim Kricheldorf et al.
Hyunyee Rosa Cho et al.
Athanasios Pseftogas,Jessica Bordini,Silvia Heltai et al.
Athanasios Pseftogas et al.
Splenic marginal zone lymphoma (SMZL) is a distinct clinical and pathological entity among marginal zone lymphomas. Genetic and microenvironmental factors leading to aberrant activation of the NF-κB pathway have been implicated in SMZL pat...
Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference [0.03%]
选择镰状细胞疾病患者进行基因添加或基于基因编辑的治疗方法：EHA特别工作组和EBMT血红蛋白病工作队共识会议报告
Lucia de Franceschi,Franco Locatelli,David Rees et al.
Lucia de Franceschi et al.
Sickle cell disease (SCD) remains associated with reduced life expectancy and poor quality of life despite improvements observed in the last decades mostly related to comprehensive care, use of hydroxycarbamide, screening to identify patien...
Cell-free DNA for detection and monitoring of extramedullary AML relapse [0.03%]
用于检测和监测髓外白血病复发的无细胞DNA
Henri C Hupe,Clara P Wienecke,Stephan Bartels et al.
Henri C Hupe et al.
Isolated extramedullary manifestations (IEM) of acute myeloid leukemia (AML) are recurrent events, especially following allogeneic hematopoietic cell transplantation (alloHCT). To date, measurable residual disease (MRD) assessment for this ...
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLA [0.03%]
弥漫性大B细胞淋巴瘤的年龄和性别特异性分子特征：来自DSHNHL/GLA临床试验的结果
Katrin S Kurz,Sophia Steinlein,Markus Kreuz et al.
Katrin S Kurz et al.
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Despite a high cure rate, too many patients show refractory (ref) or relapsed (rel) disease. This study examines the frequency of recurring gene mutations and th...
Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS [0.03%]
ELN-iMDS-Flow工作组定义的17个免疫分型核心标志物在独立的MDS患者队列中诊断潜力的验证研究
Coen R Veenstra,Canan Alhan,Theresia M Westers et al.
Coen R Veenstra et al.
Khaled M Musallam,Maria Domenica Cappellini,John B Porter et al.
Khaled M Musallam et al.
Editorial
HemaSphere. 2025 Mar 5;9(3):e70095. DOI:10.1002/hem3.70095 2025